Summary
The product Finasteride 2.5mg, manufactured by Unique Pharma, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number UN63647 EXP.02/2026, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis determined the presence of Finasteride at a concentration of 2.56 mg per tablet, exceeding the labeled claim of 2.5 mg, resulting in a variance of 2.4% above the stated concentration.
The testing process began on 14 October 2024, with the sample received on 18 October 2024, and analysis completed on 22 October 2024. While the results confirm accurate dosing, careful evaluation of reseller-submitted samples is necessary to ensure reliability across all batches. Resellers may select specific batches that meet high standards, potentially affecting the consistency of the product in the market. Independent third-party testing remains crucial for comprehensive verification. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: Finasteride 2.5mg
- Active Ingredient: Finasteride
- Batch Number: UN63647 EXP.02/2026
- Expiration Date: February 2026
- Delivery Method: Oral Tablet
Sample Acquisition and Testing
- Task Number: #50932
- Testing Ordered: 14 October 2024
- Sample Received: 18 October 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 2.5 mg (as stated on the label)
- Measured Concentration: 2.56 mg
- Accuracy: 102.4% (2.4% above the label claim)
- Variance: 2.4%
Verification Details
- Verification URL: https://janoshik.com/tests/50932_FSXUNXHNJ78Z
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis highlights the accuracy of the tested product but requires careful scrutiny as it was submitted and funded by the reseller Opitropin.EU. Resellers often select the best-performing batches for testing, which might not accurately represent the consistency of products available to consumers. While Janoshik Analytical follows stringent testing protocols, further independent validation across multiple batches would enhance the reliability of these findings.
Conclusion
The analysis confirms that Finasteride 2.5mg is slightly overdosed, with a measured concentration of 2.56 mg, which is 2.4% above the labeled claim. While this batch maintains reasonable quality control, additional testing is advised to ensure consistent dosing across the entire product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed decisions regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases; however, it can still provide useful insights when critically assessed alongside independent third-party results. Readers are encouraged to use this information responsibly.
